TOXview: a novel graphical presentation of cancer treatment toxicity profiles
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TOXview: a novel graphical presentation of cancer treatment toxicity profiles
Authors
Keywords
-
Journal
ACTA ONCOLOGICA
Volume -, Issue -, Pages 1-11
Publisher
Informa UK Limited
Online
2019-04-24
DOI
10.1080/0284186x.2019.1601256
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Potential curability and perception of received information in esophageal cancer patients
- (2017) Eleonora Pinto et al. SUPPORTIVE CARE IN CANCER
- A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer
- (2017) In Gyu Hwang et al. Journal of Geriatric Oncology
- Ramdomized 3-armed phase III study of S-1 monotherapy versus S-1/CDDP (SP) versus 5-FU/CDDP (FP) in patients (pts) with advanced gastric cancer (AGC): SC-101 study
- (2017) M. Jin et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, phase II study comparing cisplatin and high-dose 5-fluorouracil/leucovorin with paclitaxel and high-dose 5-fluorouracil/leucovorin in patients with advanced gastric cancer and adenocarcinomas of the gastroesophageal junction
- (2017) M. E. Tesselaar et al. JOURNAL OF CLINICAL ONCOLOGY
- Docetaxel-cisplatin (DC) versus 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase III study
- (2017) K. Ridwelski et al. JOURNAL OF CLINICAL ONCOLOGY
- Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis
- (2017) Emil ter Veer et al. Scientific Reports
- Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma
- (2016) S.-E. Al-Batran et al. ANNALS OF ONCOLOGY
- Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial
- (2016) H. H. Yoon et al. ANNALS OF ONCOLOGY
- Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701)
- (2016) Shigefumi Yoshino et al. EUROPEAN JOURNAL OF CANCER
- Adverse event reporting in oncology clinical trials - lost in translation?
- (2016) Shanthi Sivendran et al. Expert Opinion On Drug Safety
- Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial
- (2016) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Time for better presentation and analysis of adverse events
- (2016) Tito Mendoza LANCET ONCOLOGY
- S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial
- (2016) Shuichi Hironaka et al. LANCET ONCOLOGY
- Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254
- (2016) Gita Thanarajasingam et al. LANCET ONCOLOGY
- Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial
- (2016) Kazumasa Fujitani et al. LANCET ONCOLOGY
- Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)
- (2015) M.-H. Ryu et al. ANNALS OF ONCOLOGY
- S-1 combined with cisplatin versus cisplatin alone for the treatment of advanced gastric cancer
- (2015) Di Wu et al. ANTI-CANCER DRUGS
- Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer
- (2015) Hideaki Bando et al. Gastric Cancer
- Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer
- (2015) Jinwan Wang et al. Gastric Cancer
- A randomized phase II trial of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment versus SP randomized PII trial (XParTS II).
- (2015) Michiya Kobayashi et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium
- (2015) Manish A. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial
- (2015) Sebastian Ochenduszko et al. MEDICAL ONCOLOGY
- S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer
- (2015) Feng Du et al. MEDICINE
- Satisfaction with information and unmet information needs in men and women with cancer
- (2015) Hermann Faller et al. Journal of Cancer Survivorship
- Conducting Meta-Analyses inRwith themetaforPackage
- (2015) Wolfgang Viechtbauer Journal of Statistical Software
- Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer
- (2014) Y. Yamada et al. ANNALS OF ONCOLOGY
- Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study
- (2014) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Erratum: Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer
- (2014) W Koizumi et al. BRITISH JOURNAL OF CANCER
- Simvastatin plus capecitabine–cisplatin versus placebo plus capecitabine–cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study
- (2014) Seung Tae Kim et al. EUROPEAN JOURNAL OF CANCER
- Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)
- (2014) Lin Shen et al. Gastric Cancer
- S-1 plus oxaliplatin vs. S-1 as first-line treatment in patients with previously untreated advanced gastric cancer: a randomized phase II study
- (2014) Yiming Lu et al. JOURNAL OF CHEMOTHERAPY
- Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) Study
- (2014) Rosine Guimbaud et al. JOURNAL OF CLINICAL ONCOLOGY
- Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
- (2014) Timothy Iveson et al. LANCET ONCOLOGY
- Femur performed better than tibia in autologous transplantation during hemipelvis reconstruction
- (2014) Jiong Mei et al. World Journal of Surgical Oncology
- Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer
- (2013) X. Wang et al. Clinical & Translational Oncology
- A multicentre randomised trial comparing weekly paclitaxel+S-1 with weekly paclitaxel+5-fluorouracil for patients with advanced gastric cancer
- (2013) Dingzhi Huang et al. EUROPEAN JOURNAL OF CANCER
- Results of docetaxel plus oxaliplatin (DOCOX)±cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: Results of a randomised Phase 2 study
- (2013) Donald Richards et al. EUROPEAN JOURNAL OF CANCER
- Randomized Phase III Study of 5-Fluorouracil Continuous Infusion vs. Sequential Methotrexate and 5-Fluorouracil Therapy in Far Advanced Gastric Cancer with Peritoneal Metastasis (JCOG0106)
- (2013) K. Shirao et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Adverse Event Reporting in Cancer Clinical Trial Publications
- (2013) Shanthi Sivendran et al. JOURNAL OF CLINICAL ONCOLOGY
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- (2013) Tom Waddell et al. LANCET ONCOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer
- (2012) M. M. Eatock et al. ANNALS OF ONCOLOGY
- Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study
- (2012) A Roy et al. BRITISH JOURNAL OF CANCER
- Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer
- (2012) E Mochiki et al. BRITISH JOURNAL OF CANCER
- A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy
- (2012) Sun Jin Sym et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A randomized phase II trial of S-1-oxaliplatin versus capecitabine–oxaliplatin in advanced gastric cancer
- (2012) Gun Min Kim et al. EUROPEAN JOURNAL OF CANCER
- The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)
- (2012) Salah-Eddin Al-Batran et al. EUROPEAN JOURNAL OF CANCER
- A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer
- (2012) Kazuhiro Nishikawa et al. Gastric Cancer
- Randomized Prospective Phase II Study to Compare the Combination Chemotherapy Regimen Epirubicin, Cisplatin, and 5-Fluorouracil With Epirubicin, Cisplatin, and Capecitabine in Patients With Advanced or Metastatic Gastric Cancer
- (2011) Janja Ocvirk et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301)
- (2011) Yoshito Komatsu et al. ANTI-CANCER DRUGS
- Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)
- (2011) Hiroyuki Narahara et al. Gastric Cancer
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2011) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer
- (2011) Xiao-Dong Li WORLD JOURNAL OF GASTROENTEROLOGY
- Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study
- (2010) S. Rao et al. ANNALS OF ONCOLOGY
- A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy
- (2010) Hei-Cheul Jeung et al. CANCER
- A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer
- (2010) Jina Yun et al. EUROPEAN JOURNAL OF CANCER
- The addition of pravastatin to chemotherapy in advanced gastric carcinoma: A randomised phase II trial
- (2010) Inge R.H.M. Konings et al. EUROPEAN JOURNAL OF CANCER
- Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial
- (2010) Jaffer A. Ajani et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction
- (2009) M. Moehler et al. ANNALS OF ONCOLOGY
- Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
- (2009) Y.-K. Kang et al. ANNALS OF ONCOLOGY
- 6509 5-FU/l-LV (RPMI) versus S-1 as first-line therapy in patients with advanced gastric cancer: a randomized phase III non-inferiority trial. (ISO-5FU10 Study Group trial)
- (2009) A. Sawaki et al. EJC SUPPLEMENTS
- Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
- (2009) Narikazu Boku et al. LANCET ONCOLOGY
- Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer
- (2009) Kyung Hee Lee et al. Cancer Research and Treatment
- Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
- (2008) M. Dank et al. ANNALS OF ONCOLOGY
- A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
- (2008) J-L Lee et al. BRITISH JOURNAL OF CANCER
- Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
- (2008) Salah-Eddin Al-Batran et al. JOURNAL OF CLINICAL ONCOLOGY
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
- (2008) Wasaburo Koizumi et al. LANCET ONCOLOGY
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started